This phase Ib/II trial studies the side effects of near-infrared image guided surgical resection with indocyanine green in treating patients with head and neck cancer. Near-infrared image guided surgical resection with indocyanine green may make it easier to find and remove tumors.
Full Title of Study: “Phase 1B/2, Open-Label Study Evaluating Safety and Efficacy of Enhanced Permeability and Retention Effect for Near-Infrared Image Guided Surgical Resection of Head and Neck Cancers With Indocyanine Green”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: June 8, 2021
PRIMARY OBJECTIVES: I. To determine the safety profile of high-dose optical dye, indocyanine green, in head and neck cancer surgical patients. SECONDARY OBJECTIVES: I. Determine the efficacy of high-dose indocyanine green to identify cancer compared to surrounding normal tissue (tumor to background ratio; TBR) in head and neck cancer resections. OUTLINE: Patients receive indocyanine green intravenously (IV) on day 0 and undergo near-infrared image guided surgical resection on day 1. After completion of study treatment, patients are followed up for 14-30 days.
- Procedure: Image-Guided Surgery
- Undergo near-infrared image guided surgical resection
- Drug: Indocyanine Green Drug
- Given IV
Arms, Groups and Cohorts
- Experimental: Treatment (near-infrared image guided surgical resection)
- Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
Clinical Trial Outcome Measures
- Safety related by type, incidence, severity, seriousness, and study treatment relatedness of adverse events
- Time Frame: Up to 30 days
- Adverse events will be tabulated by treatment group and will include the number of patients for whom the event occurred, the rate of occurrence, and the severity and relationship to study drug.
- Successful tumor fluorescence imaging data gathered for all patients included in the study
- Time Frame: Up to 30 days
- The effect of indocyanine green will be assessed by changes in tumor-to-background ratio (TBR). Tumor to background (TBR) data will be generated from still images collected throughout the procedure as previously described (Heath, Deep et al.). The presence of fluorescence in normal surrounding tissue will be correlated with fluorescence within the tumor mass. The linear relationship between fluorescence and tumor size will be computed as Spearman?s correlation coefficient. Continuous variable means (e.g., fluorescence intensity) will be compared to histological quantification of tumor as measured by the greatest dimension identified on the histopathological assessment.
Participating in This Clinical Trial
- Documentation of a head and neck cancer diagnosis as evidenced by tissue biopsy. – Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed. – Planned standard of care surgery with curative intent for squamous cell carcinoma. – Have life expectancy of more than 12 weeks. – Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 1. – Hemoglobin >= 9 gm/dL. – White blood cell count > 3000/mm^3. – Platelet count >= 100,000/mm^3. – Serum creatinine =< 1.5 mg/dL. – Liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and total bilirubin) =< 1.5 times the upper reference range. – Written informed consent (and assent when applicable) obtained from subject or subject?s legal representative and ability for subject to comply with the requirements of the study. – Agree to not have radioactive iodine uptake studies done within 1 week of indocyanine green. Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. – Allergy to iodine or iodinated materials. – Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. – Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Provider of Information About this Clinical Study
- Overall Official(s)
- Abie Mendelsohn, Principal Investigator, UCLA / Jonsson Comprehensive Cancer Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.